The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Items 201–400 of 452
Kuan, Y.-C., Huang, K.-W., Lin, C.-L., Hu, C.-J., & Kao, C.-H. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.002 · Cited by 168 · cited 1×
“On the other hand, it has been recently linked to an increased dementia risk in diabetes patients [410].”
BackgroundDecker, H., Jürgensen, S., Adrover, M. F., Brito‐Moreira, J., Bomfim, T. R., Klein, W. L., Epstein, A. L., De Felice, F. G., Jerusalinsky, D., & Ferreira, S. T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07058.x · Cited by 166
Self-citationRijal Upadhaya, A., Kosterin, I., Kumar, S., von Arnim, C. A. F., Yamaguchi, H., Fändrich, M., Walter, J., & Thal, D. R. (2014) · Brain · doi:10.1093/brain/awt362 · Cited by 166
Rocchi, A., Yamamoto, S., Ting, T., Fan, Y., Sadleir, K., Wang, Y., Zhang, W., Huang, S., Levine, B., Vassar, R., et al. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006962 · Cited by 166
Nielsen, H. M., Mulder, S. D., Beliën, J. A. M., Musters, R. J. P., Eikelenboom, P., & Veerhuis, R. (2010) · Glia · doi:10.1002/glia.21004 · Cited by 165
Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
Wildburger, N. C., Esparza, T. J., LeDuc, R. D., Fellers, R. T., Thomas, P. M., Cairns, N. J., Kelleher, N. L., Bateman, R. J., & Brody, D. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-10422-x · Cited by 164
Tyrosine Phosphorylation of Pyk2 Is Selectively Regulated by Fyn During TCR Signaling
Qian, D., Lev, S., Oers, N. S. C. V., Dikic, I., Schlessinger, J., & Weiss, A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.7.1253 · Cited by 162
Targeting Fyn Kinase in Alzheimer’s Disease
Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162
Chin, J., Palop, J. J., Yu, G.-Q., Kojima, N., Masliah, E., & Mucke, L. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0277-04.2004 · Cited by 161
Izzo, N. J., Xu, J., Zeng, C., Kirk, M. J., Mozzoni, K., Silky, C., Rehak, C., Yurko, R., Look, G., Rishton, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111899 · Cited by 157
Zhang, H., Liu, H., Davies, K. J. A., Sioutas, C., Finch, C. E., Morgan, T. E., & Forman, H. J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.042 · Cited by 155
Yassine, H. N., Braskie, M. N., Mack, W. J., Castor, K. J., Fonteh, A. N., Schneider, L. S., Harrington, M. G., & Chui, H. C. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4899 · Cited by 155
Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ
Zhao, W.-Q., Lacor, P. N., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011015 · Cited by 154
Self-citationOcular changes in TgF344-AD rat model of Alzheimer's disease
Tsai, Y., Lu, B., Ljubimov, A. V., Girman, S., Ross-Cisneros, F. N., Sadun, A. A., Svendsen, C. N., Cohen, R. M., & Wang, S. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12888 · Cited by 153
Soluble and Mature Amyloid Fibrils in Drusen Deposits
Isas, J. M., Luibl, V., Johnson, L. V., Kayed, R., Wetzel, R., Glabe, C. G., Langen, R., & Chen, J. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4207 · Cited by 153
Rushworth, J. V., Griffiths, H. H., Watt, N. T., & Hooper, N. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.400358 · Cited by 153
Nanodiscs as a New Tool to Examine Lipid–Protein Interactions
Schuler, M. A., Denisov, I. G., & Sligar, S. G. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-275-9_18 · Cited by 152
Lonskaya, I., Hebron, M. L., Desforges, N. M., Schachter, J. B., & Moussa, C. E.-H. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1112-3 · Cited by 152
Domert, J., Rao, S. B., Agholme, L., Brorsson, A.-C., Marcusson, J., Hallbeck, M., & Nath, S. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.12.019 · Cited by 150
Wang, M. J., Yi, S., Han, J.-Y., Park, S. Y., Jang, J.-W., Chun, I. K., Kim, S. E., Lee, B. S., Kim, G. J., Yu, J. S., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0324-0 · Cited by 150
Vargas, J. Y., Fuenzalida, M., & Inestrosa, N. C. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0862-13.2014 · Cited by 148
Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration
Liu, P., Reed, M. N., Kotilinek, L. A., Grant, M. K. O., Forster, C. L., Qiang, W., Shapiro, S. L., Reichl, J. H., Chiang, A. C. A., Jankowsky, J. L., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.021 · Cited by 147
Na+,K+-ATPase as a docking station: protein–protein complexes of the Na+,K+-ATPase
Reinhard, L., Tidow, H., Clausen, M. V., & Nissen, P. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1039-9 · Cited by 147
RAFTK/Pyk2 Activation Is Mediated by Trans-acting Autophosphorylation in a Src-independent Manner
Park, S.-Y., Avraham, H. K., & Avraham, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313527200 · Cited by 145
Garai, K., Verghese, P. B., Baban, B., Holtzman, D. M., & Frieden, C. (2014) · Biochemistry · doi:10.1021/bi5008172 · Cited by 145
Tai, J., Liu, W., Li, Y., Li, L., & Hölscher, C. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.012 · Cited by 145
Pathways of Amyloid-β Aggregation Depend on Oligomer Shape
Barz, B., Liao, Q., & Strodel, B. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b10343 · Cited by 145
ER stress is involved in Aβ‐induced GSK‐3β activation and tau phosphorylation
Resende, R., Ferreiro, E., Pereira, C., & Oliveira, C. R. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21648 · Cited by 143
Economou, N. J., Giammona, M. J., Do, T. D., Zheng, X., Teplow, D. B., Buratto, S. K., & Bowers, M. T. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b11913 · Cited by 141
Amyloid β-42 induces neuronal apoptosis by targeting mitochondria
Han, X.-J., Hu, Y.-Y., Yang, Z.-J., Jiang, L.-P., Shi, S.-L., Li, Y.-R., Guo, M.-Y., Wu, H.-L., & Wan, Y.-Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7203 · Cited by 141
Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly
Ohnishi, T., Yanazawa, M., Sasahara, T., Kitamura, Y., Hiroaki, H., Fukazawa, Y., Kii, I., Nishiyama, T., Kakita, A., Takeda, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421182112 · Cited by 140
Esbjörner, E. K., Chan, F., Rees, E., Erdelyi, M., Luheshi, L. M., Bertoncini, C. W., Kaminski, C. F., Dobson, C. M., & Kaminski Schierle, G. S. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.03.014 · Cited by 140
Alzheimer's disease and diet: a systematic review
Yusufov, M., Weyandt, L. L., & Piryatinsky, I. (2017) · International Journal of Neuroscience · doi:10.3109/00207454.2016.1155572 · Cited by 140
Aβ Oligomers Induce Neuronal Cell Cycle Events in Alzheimer's Disease
Varvel, N. H., Bhaskar, K., Patil, A. R., Pimplikar, S. W., Herrup, K., & Lamb, B. T. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2441-08.2008 · Cited by 139
Ostapchenko, V. G., Chen, M., Guzman, M. S., Xie, Y.-F., Lavine, N., Fan, J., Beraldo, F. H., Martyn, A. C., Belrose, J. C., Mori, Y., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4081-14.2015 · Cited by 138
Ledo, J. H., Azevedo, E. P., Beckman, D., Ribeiro, F. C., Santos, L. E., Razolli, D. S., Kincheski, G. C., Melo, H. M., Bellio, M., Teixeira, A. L., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1269-16.2016 · Cited by 138
Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid‐β oligomers
Gandy, S., Simon, A. J., Steele, J. W., Lublin, A. L., Lah, J. J., Walker, L. C., Levey, A. I., Krafft, G. A., Levy, E., Checler, F., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22052 · Cited by 137
Alzheimer's Disease and the Amyloid β-Protein
Walsh, D. M., & Teplow, D. B. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00012-6 · Cited by 136
Drolle, E., Hane, F. T., Lee, B. Y., & Leonenko, Z. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.882354 · Cited by 135
Chakrabarti, S., Kumar Khemka, V., Banerjee, A., Chatterjee, G., Ganguly, A., & Biswas, A. (2015) · Aging and disease · doi:10.14336/ad.2014.002 · Cited by 134
ApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation
Sen, A., Nelson, T. J., & Alkon, D. L. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0260-15.2015 · Cited by 133
Kostylev, M. A., Kaufman, A. C., Nygaard, H. B., Patel, P., Haas, L. T., Gunther, E. C., Vortmeyer, A., & Strittmatter, S. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.643577 · Cited by 133
Mechanisms for the Insertion of Toxic, Fibril-like β-Amyloid Oligomers into the Membrane
Jang, H., Connelly, L., Teran Arce, F., Ramachandran, S., Kagan, B. L., Lal, R., & Nussinov, R. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct300916f · Cited by 133
Alzheimer’s β-peptide oligomer formation at physiologic concentrations
LeVine, H. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.08.014 · Cited by 132
FRACKOWIAK, J., ZOLTOWSKA, A., & WISNIEWSKI, H. M. (1994) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199411000-00011 · Cited by 128
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer’s disease
Kam, T.-I., Song, S., Gwon, Y., Park, H., Yan, J.-J., Im, I., Choi, J.-W., Choi, T.-Y., Kim, J., Song, D.-K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66827 · Cited by 128
Self-citationLeading Alzheimer’s theory survives drug failure
Abbott, A., & Dolgin, E. (2016) · Nature · doi:10.1038/nature.2016.21045 · Cited by 128
Nishitsuji, K., Tomiyama, T., Ishibashi, K., Ito, K., Teraoka, R., Lambert, M. P., Klein, W. L., & Mori, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080480 · Cited by 127
Self-citationArchitecture of the Alzheimer?s A�P Ion Channel Pore
Arispe, N. J. (2004) · The Journal of Membrane Biology · doi:10.1007/s00232-003-0638-7 · Cited by 127
Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126 · cited 1×
“Such tactics may be earlier intervention within the disease continuum and better criteria for patient selection [5, 108] and better biomarkers for monitoring of investigational new drugs [103], including inflammation markers to better predict complications [106].”
BackgroundBao, F., Wicklund, L., Lacor, P. N., Klein, W. L., Nordberg, A. K., & Marutle, A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.003 · Cited by 126
Self-citationBACE inhibition-dependent repair of Alzheimer’s pathophysiology
Keskin, A. D., Kekuš, M., Adelsberger, H., Neumann, U., Shimshek, D. R., Song, B., Zott, B., Peng, T., Förstl, H., Staufenbiel, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708106114 · Cited by 125
Propagation of tau pathology in Alzheimer’s disease: identification of novel therapeutic targets
Pooler, A. M., Polydoro, M., Wegmann, S., Nicholls, S. B., Spires-Jones, T. L., & Hyman, B. T. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt214 · Cited by 124
Soluble Aβ Promotes Wild-Type Tau Pathology In Vivo
Chabrier, M. A., Blurton-Jones, M., Agazaryan, A. A., Nerhus, J. L., Martinez-Coria, H., & LaFerla, F. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0172-12.2012 · Cited by 123
Davis, D. A., Bortolato, M., Godar, S. C., Sander, T. K., Iwata, N., Pakbin, P., Shih, J. C., Berhane, K., McConnell, R., Sioutas, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064128 · Cited by 123 · cited 2×
“depression-like responses [337], and reduced neurite”
Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers
Umeda, T., Ono, K., Sakai, A., Yamashita, M., Mizuguchi, M., Klein, W. L., Yamada, M., Mori, H., & Tomiyama, T. (2016) · Brain · doi:10.1093/brain/aww042 · Cited by 123
Self-citationDe Felice, F. G., & Lourenco, M. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00094 · Cited by 121
Varvel, N. H., Bhaskar, K., Kounnas, M. Z., Wagner, S. L., Yang, Y., Lamb, B. T., & Herrup, K. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39716 · Cited by 121
Purification and Characterization of Brain Clusterin
Oda, T., Pasinetti, G. M., Osterburg, H. H., Anderson, C., Johnson, S. A., & Finch, C. E. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2580 · Cited by 118
The choroid plexus-cerebrospinal fluid interface in Alzheimer′s disease: more than just a barrier
Vandenbroucke, R., Balusu, S., Brkic, M., & Libert, C. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.180372 · Cited by 118
Dohler, F., Sepulveda-Falla, D., Krasemann, S., Altmeppen, H., Schlüter, H., Hildebrand, D., Zerr, I., Matschke, J., & Glatzel, M. (2014) · Brain · doi:10.1093/brain/awt375 · Cited by 117
Kincheski, G. C., Valentim, I. S., Clarke, J. R., Cozachenco, D., Castelo-Branco, M. T. L., Ramos-Lobo, A. M., Rumjanek, V. M. B. D., Donato, J., De Felice, F. G., & Ferreira, S. T. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.04.007 · Cited by 117
Zussy, C., Brureau, A., Keller, E., Marchal, S., Blayo, C., Delair, B., Ixart, G., Maurice, T., & Givalois, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053117 · Cited by 116
Yang, T., O’Malley, T. T., Kanmert, D., Jerecic, J., Zieske, L. R., Zetterberg, H., Hyman, B. T., Walsh, D. M., & Selkoe, D. J. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0100-y · Cited by 115
Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases
Bilousova, T., Miller, C. A., Poon, W. W., Vinters, H. V., Corrada, M., Kawas, C., Hayden, E. Y., Teplow, D. B., Glabe, C., Albay, R., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.09.018 · Cited by 115
Diomede, L., Cassata, G., Fiordaliso, F., Salio, M., Ami, D., Natalello, A., Doglia, S. M., De Luigi, A., & Salmona, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.002 · Cited by 114
Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.-H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00180 · Cited by 114
Matsumura, S., Shinoda, K., Yamada, M., Yokojima, S., Inoue, M., Ohnishi, T., Shimada, T., Kikuchi, K., Masui, D., Hashimoto, S., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.181313 · Cited by 112
Aβ and NMDAR activation cause mitochondrial dysfunction involving ER calcium release
Ferreira, I. L., Ferreiro, E. B., Schmidt, J., Cardoso, J. M. R., Pereira, C., Carvalho, A. L., Oliveira, C. R., & Rego, A. C. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.006 · Cited by 111
Costa, R. O., Lacor, P. N., Ferreira, I. L., Resende, R., Auberson, Y. P., Klein, W. L., Oliveira, C. R., Rego, A. C., & Pereira, C. M. F. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00848.x · Cited by 110
Self-citationCole, G. M., & Frautschy, S. A. (2006) · Nutrition and Health · doi:10.1177/026010600601800307 · Cited by 110
Jackson, R. J., Rudinskiy, N., Herrmann, A. G., Croft, S., Kim, J. M., Petrova, V., Ramos‐Rodriguez, J. J., Pitstick, R., Wegmann, S., Garcia‐Alloza, M., et al. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13442 · Cited by 109
Sponne, I., Fifre, A., Drouet, B., Klein, C., Koziel, V., Pinçon-Raymond, M., Olivier, J.-L., Chambaz, J., & Pillot, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206745200 · Cited by 108
RAGE Ligand Upregulation of VEGF Secretion in ARPE-19 Cells
Ma, W., Lee, S. E., Guo, J., Qu, W., Hudson, B. I., Schmidt, A. M., & Barile, G. R. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0738 · Cited by 107
Oikawa, N., Kimura, N., & Yanagisawa, K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.12.005 · Cited by 106
Kumar, S., Wirths, O., Stüber, K., Wunderlich, P., Koch, P., Theil, S., Rezaei-Ghaleh, N., Zweckstetter, M., Bayer, T. A., Brüstle, O., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1546-0 · Cited by 105
Washington, P. M., Morffy, N., Parsadanian, M., Zapple, D. N., & Burns, M. P. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2013.3017 · Cited by 103 · cited 1×
“These observations are supported in TBI animal models, wherein A levels rise within 1 hour after a single mild cortical impact and continue to rise for at least 24 hours [332, 333] and are associated with increased memory impairment [334].”
BackgroundRare Individual Amyloid-β Oligomers Act on Astrocytes to Initiate Neuronal Damage
Narayan, P., Holmström, K. M., Kim, D.-H., Whitcomb, D. J., Wilson, M. R., St. George-Hyslop, P., Wood, N. W., Dobson, C. M., Cho, K., Abramov, A. Y., et al. (2014) · Biochemistry · doi:10.1021/bi401606f · Cited by 103
Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S. V., & Sierks, M. R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.068 · Cited by 103
Iulita, M. F., Allard, S., Richter, L., Munter, L.-M., Ducatenzeiler, A., Weise, C., Do Carmo, S., Klein, W. L., Multhaup, G., & Cuello, A. C. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-61 · Cited by 103
Self-citationGiralt, A., Brito, V., Chevy, Q., Simonnet, C., Otsu, Y., Cifuentes-Díaz, C., de Pins, B., Coura, R., Alberch, J., Ginés, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15592 · Cited by 102
Poon, W. W., Carlos, A. J., Aguilar, B. L., Berchtold, N. C., Kawano, C. K., Zograbyan, V., Yaopruke, T., Shelanski, M., & Cotman, C. W. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463711 · Cited by 99
Welzel, A. T., Maggio, J. E., Shankar, G. M., Walker, D. E., Ostaszewski, B. L., Li, S., Klyubin, I., Rowan, M. J., Seubert, P., Walsh, D. M., et al. (2014) · Biochemistry · doi:10.1021/bi5003053 · Cited by 98
Chabrier, M. A., Cheng, D., Castello, N. A., Green, K. N., & LaFerla, F. M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.01.007 · Cited by 97
Nunes-Tavares, N., Santos, L. E., Stutz, B., Brito-Moreira, J., Klein, W. L., Ferreira, S. T., & de Mello, F. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.321448 · Cited by 95
Self-citationWang, D., Govindaiah, G., Liu, R., De Arcangelis, V., Cox, C. L., & Xiang, Y. K. (2010) · The FASEB Journal · doi:10.1096/fj.10-156661 · Cited by 95
Umeda, T., Tomiyama, T., Kitajima, E., Idomoto, T., Nomura, S., Lambert, M. P., Klein, W. L., & Mori, H. (2012) · Life Sciences · doi:10.1016/j.lfs.2011.12.022 · Cited by 93
Self-citationCerf, E., Gustot, A., Goormaghtigh, E., Ruysschaert, J.-M., & Raussens, V. (2011) · The FASEB Journal · doi:10.1096/fj.10-175976 · Cited by 92
Protein homeostasis of a metastable subproteome associated with Alzheimer’s disease
Kundra, R., Ciryam, P., Morimoto, R. I., Dobson, C. M., & Vendruscolo, M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618417114 · Cited by 92
Di Scala, C., Troadec, J., Lelièvre, C., Garmy, N., Fantini, J., & Chahinian, H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12390 · Cited by 91
Hodgson, N., Trivedi, M., Muratore, C., Li, S., & Deth, R. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130101 · Cited by 91
Postsynaptic Clustering and Activation of Pyk2 by PSD-95
Bartos, J. A., Ulrich, J. D., Li, H., Beazely, M. A., Chen, Y., MacDonald, J. F., & Hell, J. W. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4992-08.2010 · Cited by 90
Pistollato, F., Cano, S. S., Elío, I., Vergara, M. M., Giampieri, F., & Battino, M. A. (2016) · Advances in Nutrition · doi:10.3945/an.115.011775 · Cited by 90
Age-related progression of tau pathology in brains of baboons
Schultz, C., Hubbard, G. B., Rüb, U., Braak, E., & Braak, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00176-7 · Cited by 89
Vincent, A. S., Roebuck‐Spencer, T. M., & Cernich, A. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.006 · Cited by 89
Saul, A., Sprenger, F., Bayer, T. A., & Wirths, O. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.003 · Cited by 88 · cited 1×
“Co-expression of mutant tau and mutant A appears to support a synergistic action, showing dramatically increased pTau aggregation and spread, inflammation, and synapse loss [296, 298, 299].”
BackgroundAβ1-42 monomers or oligomers have different effects on autophagy and apoptosis
Guglielmotto, M., Monteleone, D., Piras, A., Valsecchi, V., Tropiano, M., Ariano, S., Fornaro, M., Vercelli, A., Puyal, J., Arancio, O., et al. (2014) · Autophagy · doi:10.4161/auto.30001 · Cited by 87
Kim, B., Park, J., Chang, K., & Lee, D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.11.015 · Cited by 87
Brody, D. L., Jiang, H., Wildburger, N., & Esparza, T. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0293-3 · Cited by 87
How the Wnt signaling pathway protects from neurodegeneration: the mitochondrial scenario
Arrázola, M. S., Silva-Álvarez, C., & Inestrosa, N. C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00166 · Cited by 86
Gleckman, A. M., Bell, M. D., Evans, R. J., & Smith, T. W. (1999) · Archives of Pathology and Laboratory Medicine · doi:10.5858/1999-123-0146-daiiiw · Cited by 86
Vieira, M. N. N., Forny‐Germano, L., Saraiva, L. M., Sebollela, A., Martinez, A. M. B., Houzel, J., De Felice, F. G., & Ferreira, S. T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04809.x · Cited by 85
Chang, L., Bakhos, L., Wang, Z., Venton, D. L., & Klein, W. L. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:305 · Cited by 85
Self-citationCerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia
Chen, D., Wang, J., Zhang, L., Wang, Y., & Gao, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170032 · Cited by 85
Brito-Moreira, J., Lourenco, M. V., Oliveira, M. M., Ribeiro, F. C., Ledo, J. H., Diniz, L. P., Vital, J. F. S., Magdesian, M. H., Melo, H. M., Barros-Aragão, F., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.761189 · Cited by 84
Pitt, J., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X.-W., Nandamuri, S., Gomes, F. C. A., DiNunno, N., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0416 · Cited by 84
Self-citationGunn, A. P., Wong, B. X., Johanssen, T., Griffith, J. C., Masters, C. L., Bush, A. I., Barnham, K. J., Duce, J. A., & Cherny, R. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655183 · Cited by 83
Amyloid β‐induced astrogliosis is mediated by β1‐integrin via NADPH oxidase 2 in Alzheimer's disease
Wyssenbach, A., Quintela, T., Llavero, F., Zugaza, J. L., Matute, C., & Alberdi, E. (2016) · Aging Cell · doi:10.1111/acel.12521 · Cited by 82
BACE inhibitor bust in Alzheimer trial
Mullard, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.43 · Cited by 82
Structural differences between amyloid beta oligomers
Breydo, L., Kurouski, D., Rasool, S., Milton, S. C. F., Wu, J., Uversky, V. N., Lednev, I. K., & Glabe, C. G. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.122 · Cited by 81
Héraud, C., Goufak, D., Ando, K., Leroy, K., Suain, V., Yilmaz, Z., De Decker, R., Authelet, M., Laporte, V., Octave, J.-N., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.010 · Cited by 80 · cited 1×
“Co-expression of mutant tau and mutant A appears to support a synergistic action, showing dramatically increased pTau aggregation and spread, inflammation, and synapse loss [296, 298, 299].”
BackgroundKitiyanant, N., Kitiyanant, Y., Svendsen, C. N., & Thangnipon, W. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0592-1 · Cited by 80
Tauopathic Changes in the Striatum of A53T α-Synuclein Mutant Mouse Model of Parkinson's Disease
Wills, J., Credle, J., Haggerty, T., Lee, J.-H., Oaks, A. W., & Sidhu, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017953 · Cited by 79
Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders
Batarseh, Y., Duong, Q.-V., Mousa, Y., Al Rihani, S., Elfakhri, K., & Kaddoumi, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030338 · Cited by 79
Amyloid-β and Tau Pathology of Alzheimer's Disease Induced by Diabetes in a Rabbit Animal Model
Bitel, C. L., Kasinathan, C., Kaswala, R. H., Klein, W. L., & Frederikse, P. H. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120571 · Cited by 78
Self-citationKang, M. K., Lee, J., Nguyen, A. H., & Sim, S. J. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.05.017 · Cited by 78
Hori, Y., Takeda, S., Cho, H., Wegmann, S., Shoup, T. M., Takahashi, K., Irimia, D., Elmaleh, D. R., Hyman, B. T., & Hudry, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586602 · Cited by 78
Blennow, K., & Zetterberg, H. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00345 · Cited by 76
Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice
Umeda, T., Maekawa, S., Kimura, T., Takashima, A., Tomiyama, T., & Mori, H. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1259-1 · Cited by 76
Haas, L. T., & Strittmatter, S. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.720664 · Cited by 75
Association of traumatic brain injury and Alzheimer disease onset: A systematic review
Julien, J., Joubert, S., Ferland, M. C., Frenette, L. C., Boudreau-Duhaime, M.-M., Malo-Véronneau, L., & de Guise, É. (2017) · Annals of Physical and Rehabilitation Medicine · doi:10.1016/j.rehab.2017.03.009 · Cited by 75
Phase II clinical trials of anti–amyloid β antibodies: When is enough, enough?
Gold, M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.005 · Cited by 75
Caetano, F. A., Beraldo, F. H., Hajj, G. N. M., Guimaraes, A. L., Jürgensen, S., Wasilewska-Sampaio, A. P., Hirata, P. H. F., Souza, I., Machado, C. F., Wong, D. Y.-L., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07225.x · Cited by 74
Upadhaya, A. R., Lungrin, I., Yamaguchi, H., Fändrich, M., & Thal, D. R. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01306.x · Cited by 74
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 74
Dal Prà, I., Chiarini, A., Gui, L., Chakravarthy, B., Pacchiana, R., Gardenal, E., Whitfield, J. F., & Armato, U. (2015) · The Neuroscientist · doi:10.1177/1073858414529828 · Cited by 74
Urban traffic-derived nanoparticulate matter reduces neurite outgrowth via TNFα in vitro
Cheng, H., Davis, D. A., Hasheminassab, S., Sioutas, C., Morgan, T. E., & Finch, C. E. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0480-3 · Cited by 73
Ryan, T. M., Roberts, B. R., McColl, G., Hare, D. J., Doble, P. A., Li, Q.-X., Lind, M., Roberts, A. M., Mertens, H. D. T., Kirby, N., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2912-14.2015 · Cited by 72
Mc Donald, J. M., O'Malley, T. T., Liu, W., Mably, A. J., Brinkmalm, G., Portelius, E., Wittbold, W. M., Frosch, M. P., & Walsh, D. M. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.01.005 · Cited by 72
Disruption of neocortical histone H3 homeostasis by soluble Aβ: implications for Alzheimer's disease
Lithner, C. U., Lacor, P. N., Zhao, W.-Q., Mustafiz, T., Klein, W. L., Sweatt, J. D., & Hernandez, C. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.028 · Cited by 72
Self-citationTakeda, S., Hashimoto, T., Roe, A. D., Hori, Y., Spires‐Jones, T. L., & Hyman, B. T. (2013) · The FASEB Journal · doi:10.1096/fj.13-229666 · Cited by 72
Aβ42 neurotoxicity in primary co-cultures: effect of apoE isoform and Aβ conformation
Manelli, A. M., Bulfinch, L. C., Sullivan, P. M., & LaDu, M. J. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.024 · Cited by 72
Kretner, B., Trambauer, J., Fukumori, A., Mielke, J., Kuhn, P., Kremmer, E., Giese, A., Lichtenthaler, S. F., Haass, C., Arzberger, T., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505952 · Cited by 72
Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Wang, C., & Huang, Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018381108 · Cited by 71
O’Malley, T. T., Oktaviani, N. A., Zhang, D., Lomakin, A., O’Nuallain, B., Linse, S., Benedek, G. B., Rowan, M. J., Mulder, F. A. A., & Walsh, D. M. (2014) · Biochemical Journal · doi:10.1042/bj20140219 · Cited by 70
Drosophila Models of Alzheimer's Disease: Advances, Limits, and Perspectives
Bouleau, S., & Tricoire, H. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142802 · Cited by 69
Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease
Jongbloed, W., Bruggink, K. A., Kester, M. I., Visser, P.-J., Scheltens, P., Blankenstein, M. A., Verbeek, M. M., Teunissen, C. E., & Veerhuis, R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142136 · Cited by 68 · cited 2×
“A Os can be extracellular in vivo, existing in CSF [32, 34, 35, 165] and in interstitial fluid [166].”
BackgroundUrban air pollutants reduce synaptic function of CA 1 neurons via an NMDA/NȮ pathway in vitro
Davis, D. A., Akopian, G., Walsh, J. P., Sioutas, C., Morgan, T. E., & Finch, C. E. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12395 · Cited by 68
Beraldo, F. H., Ostapchenko, V. G., Caetano, F. A., Guimaraes, A. L. S., Ferretti, G. D. S., Daude, N., Bertram, L., Nogueira, K. O. P. C., Silva, J. L., Westaway, D., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738286 · Cited by 68
D’Cunha, N. M., Georgousopoulou, E. N., Dadigamuwage, L., Kellett, J., Panagiotakos, D. B., Thomas, J., McKune, A. J., Mellor, D. D., & Naumovski, N. (2018) · British Journal of Nutrition · doi:10.1017/s0007114517003452 · Cited by 68
Szczepankiewicz, O., Linse, B., Meisl, G., Thulin, E., Frohm, B., Sala Frigerio, C., Colvin, M. T., Jacavone, A. C., Griffin, R. G., Knowles, T., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b07849 · Cited by 67
Different effects of Alzheimer's peptide Aβ(1–40) oligomers and fibrils on supported lipid membranes
Canale, C., Seghezza, S., Vilasi, S., Carrotta, R., Bulone, D., Diaspro, A., Biagio, P. L. S., & Dante, S. (2013) · Biophysical Chemistry · doi:10.1016/j.bpc.2013.07.010 · Cited by 65
Price, K. A., Varghese, M., Sowa, A., Yuk, F., Brautigam, H., Ehrlich, M. E., & Dickstein, D. L. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-41 · Cited by 65
Krishna, K., Behnisch, T., & Sajikumar, S. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150838 · Cited by 64
Persistence of Aβ seeds in APP null mouse brain
Ye, L., Fritschi, S. K., Schelle, J., Obermüller, U., Degenhardt, K., Kaeser, S. A., Eisele, Y. S., Walker, L. C., Baumann, F., Staufenbiel, M., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4117 · Cited by 63
Rubenstein, R., Chang, B., Grinkina, N., Drummond, E., Davies, P., Ruditzky, M., Sharma, D., Wang, K., & Wisniewski, T. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0435-7 · Cited by 62
On the subject of rigor in the study of amyloid β-protein assembly
Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt203 · Cited by 61
Sarkar, B., Das, A. K., & Maiti, S. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00084 · Cited by 60
Astrocytic glutamatergic transporters are involved in Aβ-induced synaptic dysfunction
Huang, S., Tong, H., Lei, M., Zhou, M., Guo, W., Li, G., Tang, X., Li, Z., Mo, M., Zhang, X., et al. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.011 · Cited by 60
Targeting Insulin Signaling for the Treatment of Alzheimer's Disease
Chen, Y., Zhang, J., Zhang, B., & Gong, C.-X. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150813142423 · Cited by 59
Evangelisti, E., Wright, D., Zampagni, M., Cascella, R., Fiorillo, C., Bagnoli, S., Relini, A., Nichino, D., Scartabelli, T., Nacmias, B., et al. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310020004 · Cited by 59
Xiao, C., Davis, F. J., Chauhan, B. C., Viola, K. L., Lacor, P. N., Velasco, P. T., Klein, W. L., & Chauhan, N. B. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122419 · Cited by 59
Self-citationStabilization of dynamic microtubules by mDia1 drives Tau-dependent Aβ1–42 synaptotoxicity
Qu, X., Yuan, F. N., Corona, C., Pasini, S., Pero, M. E., Gundersen, G. G., Shelanski, M. L., & Bartolini, F. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201701045 · Cited by 59
Progression of Seed‐Induced A β Deposition within the Limbic Connectome
Ye, L., Hamaguchi, T., Fritschi, S. K., Eisele, Y. S., Obermüller, U., Jucker, M., & Walker, L. C. (2015) · Brain Pathology · doi:10.1111/bpa.12252 · Cited by 58
Heat shock treatment reduces beta amyloid toxicity in vivo by diminishing oligomers
Wu, Y., Cao, Z., Klein, W. L., & Luo, Y. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.013 · Cited by 57
Self-citationRui, Y., & Zheng, J. Q. (2016) · Molecular Brain · doi:10.1186/s13041-016-0261-z · Cited by 57
Toxicity mediated by soluble oligomers of β‐amyloid(1–42) on cholinergic SN56.B5.G4 cells
Heinitz, K., Beck, M., Schliebs, R., & Perez‐Polo, J. R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04015.x · Cited by 56
Ikonomović, M. D., Mi, Z., & Abrahamson, E. E. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.11.003 · Cited by 56
Sharma, M., Dierkes, T., & Sajikumar, S. (2017) · Aging Cell · doi:10.1111/acel.12634 · Cited by 56
Microglial activation depends on beta‐amyloid conformation: role of the formylpeptide receptor 2
Heurtaux, T., Michelucci, A., Losciuto, S., Gallotti, C., Felten, P., Dorban, G., Grandbarbe, L., Morga, E., & Heuschling, P. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06783.x · Cited by 55
Velasco, P. T., Heffern, M. C., Sebollela, A., Popova, I. A., Lacor, P. N., Lee, K. B., Sun, X., Tiano, B. N., Viola, K. L., Eckermann, A. L., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300122k · Cited by 55
Self-citationSite-specific aspartic acid isomerization regulates self-assembly and neurotoxicity of amyloid-β
Sugiki, T., & Utsunomiya‐Tate, N. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.084 · Cited by 55
Proline-Rich Tyrosine Kinase 2 Regulates Hippocampal Long-Term Depression
Hsin, H., Kim, M. J., Wang, C.-F., & Sheng, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1029-10.2010 · Cited by 55
Peters, C., Espinoza, M. P., Gallegos, S., Opazo, C., & Aguayo, L. G. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.019 · Cited by 55
Octodon degus : A Model for the Cognitive Impairment Associated with A lzheimer's Disease
Tarragón, E., Lopez, D., Estrada, C. M., Cuello, A. M. G., Schenker, E., Pifferi, F., Bordet, R., Richardson, J. C., & Herrero, M. T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12125 · Cited by 54
Zou, K., Liu, J., Watanabe, A., Hiraga, S., Liu, S., Tanabe, C., Maeda, T., Terayama, Y., Takahashi, S., Michikawa, M., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.053 · Cited by 53
Critical analysis of Alzheimer rsquo s amyloid-beta nbsp toxicity to mitochondria
Kaminsky, Y. G. (2015) · Frontiers in Bioscience · doi:10.2741/4304 · Cited by 52
Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport
Sherman, M. A., LaCroix, M., Amar, F., Larson, M. E., Forster, C., Aguzzi, A., Bennett, D. A., Ramsden, M., & Lesné, S. E. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1899-16.2016 · Cited by 52
Drews, A., Flint, J., Shivji, N., Jönsson, P., Wirthensohn, D., De Genst, E., Vincke, C., Muyldermans, S., Dobson, C., & Klenerman, D. (2016) · Scientific Reports · doi:10.1038/srep31910 · Cited by 51
Shimada, H., Ataka, S., Tomiyama, T., Takechi, H., Mori, H., & Miki, T. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000330017 · Cited by 50
El‐Shimy, I. A., Heikal, O. A., & Hamdi, N. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.10.024 · Cited by 50
Yang, W., Ma, K., Chen, X. L., Shi, L., Bu, G., Hu, X. D., Han, H., Liu, Y., & Qian, Y. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.08.013 · Cited by 49
Ganzinger, K. A., Narayan, P., Qamar, S. S., Weimann, L., Ranasinghe, R. T., Aguzzi, A., Dobson, C. M., McColl, J., St. George‐Hyslop, P., & Klenerman, D. (2014) · ChemBioChem · doi:10.1002/cbic.201402377 · Cited by 49
Pérez, J. L. M., Carrero, I., Gonzalo, P., Arévalo‐Serrano, J., Anquela, J. M. S., Ortega, F. J., Rodríguez, M. J., & Gonzalo‐Ruiz, A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.10.013 · Cited by 48
Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers
Nogalska, A., D’Agostino, C., Engel, W. K., Klein, W. L., & Askanas, V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0737-3 · Cited by 48
Self-citationPedrini, S., Thomas, C., Brautigam, H., Schmeidler, J., Ho, L., Fraser, P., Westaway, D., Hyslop, P. S., Martins, R. N., Buxbaum, J. D., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-40 · Cited by 48
Gatson, J. W., Warren, V., Abdelfattah, K., Wolf, S., Hynan, L. S., Moore, C., Diaz-Arrastia, R., Minei, J. P., Madden, C., & Wigginton, J. G. (2013) · Journal of Neurosurgery · doi:10.3171/2013.2.jns121771 · Cited by 47
Functional Interaction Between Na/K-ATPase and NMDA Receptor in Cerebellar Neurons
Akkuratov, E. E., Lopacheva, O. M., Kruusmägi, M., Lopachev, A. V., Shah, Z. A., Болдырев, А. А., & Liu, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8975-3 · Cited by 47
Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes
Knight, E. M., Kim, S. H., Kottwitz, J. C., Hatami, A., Albay, R., Suzuki, A., Lublin, A., Alberini, C. M., Klein, W. L., Szabo, P., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000237 · Cited by 47
Self-citationGalante, D., Ruggeri, F. S., Dietler, G., Pellistri, F., Gatta, E., Corsaro, A., Florio, T., Perico, A., & D’Arrigo, C. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.08.037 · Cited by 47
Bobich, J. A., Zheng, Q., & Campbell, A. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6305 · Cited by 46
Reversible Inactivation of Superoxide‐Sensitive Aconitase in Aβ1‐42‐Treated Neuronal Cell Lines
Longo, V. D., Viola, K. L., Klein, W. L., & Finch, C. E. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751977.x · Cited by 46
Self-citationConicella, A. E., & Fawzi, N. L. (2014) · Biochemistry · doi:10.1021/bi500131a · Cited by 46
Peters, C., Fernandez-Perez, E. J., Burgos, C. F., Espinoza, M. P., Castillo, C., Urrutia, J. C., Streltsov, V. A., Opazo, C., & Aguayo, L. G. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.001 · Cited by 46
TGF-β1 prevents rat retinal insult induced by amyloid-β (1–42) oligomers
Fisichella, V., Giurdanella, G., Platania, C. B. M., Romano, G. L., Leggio, G. M., Salomone, S., Drago, F., Caraci, F., & Bucolo, C. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.002 · Cited by 46
Optic Nerve Damage in Shaken Baby Syndrome
Gleckman, A. M., Evans, R. J., Bell, M. D., & Smith, T. W. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0251-ondisb · Cited by 44
Prà, I. D., Chiarini, A., Pacchiana, R., Gardenal, E., Chakravarthy, B., Whitfield, J., & Armato, U. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140828214701 · Cited by 44
Metabolic Dysfunction of Astrocyte: An Initiating Factor in Beta-amyloid Pathology?
Yan, L., Xiao, M., Chen, R., & Cai, Z. (2013) · PubMed · Cited by 44
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy
Hendrix, J. A., Bateman, R. J., Brashear, H. R., Duggan, C., Carrillo, M. C., Bain, L. J., DeMattos, R., Katz, R. G., Ostrowitzki, S., Siemers, E., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.007 · Cited by 44
Aβ peptide enhances focal adhesion kinase/Fyn association in a rat CNS nerve cell line
Zhang, C., Qiu, H. E., Krafft, G. A., & Klein, W. L. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12761-0 · Cited by 43
Self-citationNeuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain
Patel, A. N., & Jhamandas, J. H. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002134 · Cited by 43
Cheng, M. H., Santich, B. H., Xu, H., Ahmed, M., Huse, M., & Cheung, N. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1168557 · Cited by 43
Structural dynamics of the ΔE22 (Osaka) familial Alzheimer’s disease-linked amyloid β-protein
Inayathullah, M., & Teplow, D. B. (2011) · Amyloid · doi:10.3109/13506129.2011.580399 · Cited by 42
Morkuniene, R., Cizas, P., Jankeviciute, S., Petrolis, R., Arandarcikaite, O., Krisciukaitis, A., & Borutaite, V. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23510 · Cited by 41
Beta-Amyloid Oligomers Activate Apoptotic BAK Pore for Cytochrome c Release
Kim, J., Yang, Y., Song, S. S., Na, J., Oh, K. J., Jeong, C., Yu, Y. G., & Shin, Y. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2014.07.074 · Cited by 41
Specific Domains of Aβ Facilitate Aggregation on and Association with Lipid Bilayers
Yates, E. A., Owens, S. L., Lynch, M. F., Cucco, E. M., Umbaugh, C. S., & Legleiter, J. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.03.022 · Cited by 41
Lee, J., Gillman, A. L., Jang, H., Ramachandran, S., Kagan, B. L., Nussinov, R., & Arce, F. T. (2014) · Biochemistry · doi:10.1021/bi500587p · Cited by 41
Rapid amyloid‐β oligomer and protofibril accumulation in traumatic brain injury
Abu Hamdeh, S., Waara, E. R., Möller, C., Söderberg, L., Basun, H., Alafuzoff, I., Hillered, L., Lannfelt, L., Ingelsson, M., & Marklund, N. (2018) · Brain Pathology · doi:10.1111/bpa.12532 · Cited by 41
Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex
Leung, E., Guo, L., Bu, J., Maloof, M., Khoury, J. E., & Geula, C. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.025 · Cited by 40
Solanezumab and the amyloid hypothesis for Alzheimer’s disease
Le Couteur, D. G., Hunter, S., & Brayne, C. (2016) · BMJ · doi:10.1136/bmj.i6771 · Cited by 40
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“121 – 124 Moreover, other genetic risk factors, 125,126 cardiovascular health issues (such as diabetes, hypercholesterolemia), and lifestyle factors (such as diet and sleep) 127 have also been extensively studied in recent years for their relationship with A β metabolism in SAD.”
BackgroundAlzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
Half a century of amyloids: past, present and future
Ke, P. C., Zhou, R., Serpell, L. C., Riek, R., Knowles, T. P. J., Lashuel, H. A., Gazit, E., Hamley, I. W., Davis, T. P., Fändrich, M., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00199a · Cited by 568
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.